Navigating Neurological Disease States and Treatment Options

A Comprehensive Overview with Insights from TeraRecon's Neurology Suite

TERARECON
A ConcertAI Company

INTRODUCTION:

Neurological diseases represent a significant and growing healthcare challenge worldwide. These conditions affect both the central and peripheral nervous systems, leading to various physical, cognitive, and behavioral impairments.



Detecting and treating brain tumors present significant challenges due to their location, invasive nature, and heterogeneity.

Time is of the essence for clinical teams that are detecting and treating many neurological diseases. Many of these are potentially urgent conditions, such as stroke, injuries, etc. In other areas, such as neurodegenerative diseases, early detection and monitoring of progression is essential. However, the challenge is often unnecessarily difficult because of the limited information available in real-time, combined with inefficient communication channels across specialties which may create extra work for physicians and clinicians—potentially delaying time to diagnosis or treatment.

The impact of neurological diseases and any delays in treatment of the patients, families, and society is profound, often resulting in reduced quality of life and increased healthcare costs.[1]

> “TeraRecon’s Neurology Suite ensures increased productivity, consistency, reproducibility, and easy result communication; and offers dedicated tools for neurological disorders. TeraRecon’s solutions solve challenges across the care continuum to provide advanced patient care, increase patient outcomes, and reduce the financial burden of neurological diseases.
>
> — **Utkarsha Soundankar**
> **Senior Research Analyst**

In this book, we will explore various neurological diseases, their clinical manifestations, current treatment approaches, and the potential of cutting-edge AI-powered solutions within TeraRecon’s Neurology Suite that can be leveraged to support physician led diagnosis and personalized treatment plans.

TeraRecon and their third-party partners; Combinostics, Imaging Biometrics, and Cercare Medical, effectively allow clinicians to address multiple challenges, such as delays in diagnosis and lack of care team collaboration in neurological disease management. The Neurology Suite is a comprehensive vendor-neutral solution that aids in neuroimaging analysis and interpretation of treatment decisions.[2]

1 https://pubmed.ncbi.nlm.nih.gov/27227247/

2 Frost & Sullivan – 2023 Company of the Year award for AI best practices.

TERARECON

TERARECON'S NEUROLOGY SUITE PROVIDES PHYSICIAN SUPPORT ACROSS VARIOUS NEUROLOGICAL CONDITIONS

Stroke

A stroke is a brain attack. It is a sudden interruption of continuous blood flow to the brain and a medical emergency. A stroke occurs when a blood vessel in the brain becomes blocked or narrowed, or when a blood vessel bursts and spills blood into the brain. Just like a heart attack, a stroke requires immediate medical attention.

Some brain cells die because they stop getting the oxygen and nutrients needed to function. Other brain cells die because they are damaged by sudden bleeding in or around the brain. Some brain cells die quickly but many linger in a compromised or weakened state for several hours. Stroke causes permanent brain damage over minutes to hours.[3]

Delays in diagnosing acute neurological conditions such as stroke are one of the major industry challenges, resulting in long-term disabilities and, in some cases, even death. There is a common saying for neurological diseases—Time is Brain—which means the duration the brain does not get oxygen determines the extent of the lasting damage; the shorter the time the brain is without perfusion, the lesser the lasting damage. Solutions that can rapidly diagnose neurological diseases and reduce door-to-treatment time are vital.[4]

Neuro-Oncology:

Neuro-Oncology deals with tumors and cancers that develop in the brain and spinal cord.[5] Detecting and treating brain tumors present significant challenges due to their location, invasive nature, and heterogeneity. The blood-brain barrier limits the effectiveness of treatments, and tumors may recur even after successful therapy. Misdiagnosis and limited treatment options further complicate the process. Neurological complications and impacts on quality of life add to the difficulties, and access to specialized care can be an issue. Nonetheless, ongoing research and medical advancements offer hope for improved outcomes in the future.

Multiple Sclerosis:

Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system. Multiple sclerosis (MS) poses challenges in diagnosis due to its diverse symptoms and lack of definitive tests. The disease can present in various clinical forms, including relapsing-remitting, secondary progressive, primary progressive, and progressive-relapsing. Advancements in disease-modifying therapies (DMTs) have been made, including oral medications, monoclonal antibodies, and personalized medicine. Combination therapies and remyelination strategies are also being explored. Early detection and tailored treatments offer hope for improved outcomes and quality of life for MS patients.[6]

3 https://www.ninds.nih.gov/health-information/disorders/stroke
4 Frost & Sullivan – 2023 Company of the Year award for AI best practices.
5 https://www.news-medical.net/health/What-is-Neurooncology.aspx
6 https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269

Dementia/Alzheimer's:

Dementia, with Alzheimer's disease being the most common cause, poses a growing public health concern. Dementia is a progressive neurological condition that affects cognitive functions and leads to behavioral changes.[7] Early detection is essential for appropriate treatment and future planning. Differential diagnostic methods include cognitive/ neuropsychological testing and brain imaging are critical in determining the true underlying problem, as it is also possible the patient could be suffering from other dementing diseases and not Alzheimer's. Managing dementia can involve medication and require confirmation of amyloid positivity which can be done using either amyloid PET or CSF biomarkers but novel blood-based biomarkers are also coming. Cognitive stimulation, physical exercise, creating a safe environment, support groups, caregiver support, legal and financial planning, and palliative care are also essential components to dementia and Alzheimer's patient care. Until now only symptomatic care has been available but finally we are at the dawn of new disease-modifying treatments to Alzheimer's disease, emphasizing also the role of early and accurate diagnosis. A comprehensive approach improves the quality of life for patients and supports their families.

Epilepsy:

Epilepsy is the fourth most common neurological disorder[8] characterized by recurrent seizures. Accurately classifying seizures and providing precise diagnoses to guide effective treatment decisions for patients is critically important. Achieving seizure control is essential to enhance their quality of life. Treatment options range from antiepileptic medications to surgical interventions like epilepsy surgery, Vagus nerve stimulation (VNS), and responsive neurostimulation (RNS). Personalized treatment plans and close monitoring are essential for optimal outcomes and patient well-being in managing epilepsy.

Neurovascular Diseases:

Neurovascular disease is a leading cause of adult disabilities and death and includes any abnormality of the blood vessels within or supplying blood to the brain and spine.[9] This includes narrowing of the arteries, which decreases blood flow to the brain and increases the risk of a stroke. Other conditions include intracranial stenosis, cerebral small vessel disease, and vasospasm. Additionally, a neurovascular disease may cause a weakening of the arteries that can lead to brain aneurysms and other conditions that increase the risk of a stroke.

Moyamoya Disease:

Moyamoya disease is a rare cerebrovascular disorder characterized by the progressive narrowing of blood vessels in the brain. We'll explore the distinctive features of this condition, diagnostic approaches, and the importance of early surgical intervention.[10]

---

7 https://pubmed.ncbi.nlm.nih.gov/27227247/

8 https://www.epilepsy.com/what-is-epilepsy

9 https://www.vmfh.org/our-services/center-for-neurosciences-spine/neurovascular-disease

10 https://www.ninds.nih.gov/health-information/disorders/moyamoya-disease#:~:text=Moyamoya%20disease%20is%20a%20rare,vessels%20compensating%20for%20the%20blockage.

Traumatic Brain Injury:

Traumatic Brain Injury (TBI) results from head trauma due to falls or other accidents, very often in young athletes. Like with all injuries there is a spectrum of TBI severity, from mild concussions to severe brain damage. This complexity in severity and treatment emphasizes the significance of prompt assessment, management, and rehabilitative strategies.[11]

Subarachnoid Intracerebral Hemorrhage:

Subarachnoid Intracerebral Hemorrhage refers to bleeding within the space surrounding the brain.[12] As clinicians, you know how important time is to complete imaging, surgical interventions, and post-bleed care.

As advancements in medical technology and artificial intelligence continue to emerge, there is a great opportunity to revolutionize the way we approach neurological care, from diagnosis to personalized treatment plans. Through exploring the potential of AI-powered solutions and the benefits of collaboration between companies like Combinostics, Imaging Biometrics, and CerCare, we can enhance patient outcomes and improve the overall quality of neurological care.

Furthermore, we will understand how TeraRecon's Neurology Suite on the Eureka Clinical AI Platform can streamline individual point solutions and workflow across the patient care pathway, ultimately enhancing the way clinicians diagnose and treat neurological conditions. Together, let us explore these advancements and pave the way for improved patient care and clinical excellence in neurology.

11 https://www.mayoclinic.org/diseases-conditions/traumatic-brain-injury/symptoms-causes/syc-20378557

12 https://www.hopkinsmedicine.org/health/conditions-and-diseases/subarachnoid-hemorrhage#:~:text=A%20subarachnoid%20hemorrhage%20means%20that,increasing%20pressure%20on%20the%20brain.

CURRENT APPROACHES TO NEUROLOGICAL DISEASE TREATMENT

Conventional Treatments and Limitations

In the field of neurology, conventional treatments have long been the backbone of managing neurological diseases.[13] These treatments are based on established protocols and medical knowledge, aimed at alleviating symptoms, slowing disease progression, and improving patients' overall quality of life. While conventional treatments have been effective in many cases, they do come with certain limitations that pose challenges to providing optimal care to patients.

Medications:

Medications may be commonly prescribed to manage neurological conditions. For instance, antiepileptic drugs can be used to control seizures in patients with epilepsy, while dopaminergic agents are likely prescribed to manage motor symptoms in Parkinson's disease . However, not all patients respond favorably to medications, and some may experience side effects that can impact compliance and treatment adherence .

Physical and Occupational Therapy:

Physical and occupational therapies play a vital role in rehabilitation following neurological events like stroke or traumatic brain injury. These therapies help patients in their attempts to regain mobility, improve muscle strength, and relearn essential daily living activities. However, therapy outcomes can vary depending on the patient's condition, and access to specialized rehabilitation services may be limited in some regions.

Surgical Interventions:

In cases of severe neurological diseases, surgical interventions may be necessary.[14] For example, in neurovascular diseases like intracranial stenosis or Moyamoya disease, surgical procedures like angioplasty or bypass surgeries are employed to try and restore blood flow to the brain. Despite their benefits, surgical procedures carry inherent risks, and not all patients may be suitable candidates.[15]

13 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202568/
14 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202568/
15 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202568/

TERARECON

LEVERAGING AI SOLUTIONS FOR IMPROVED NEUROLOGICAL DISEASE IDENTIFICATION AND TREATMENT

As neurological physicians and clinicians, you are constantly striving to enhance your ability to identify and treat neurological diseases effectively. The integration of AI-powered solutions has opened up new avenues for innovation, providing you with powerful tools to help revolutionize your approach and efficiency when providing neurological care. Three prominent players in this field are Combinostics, Imaging Biometrics, and Cercare Medical.

TERARECON

COMBINOSTICS

Combinostics

Combinostic's Mission

Combinostics is committed to persistently innovating, with the goal of bolstering clinicians' ability to provide the highest quality care for their patients with neurological disorders.

Combinostic's Background and Expertise

Drawing on a rich, collective background in science and research, Combinostics leverages their understanding of neurological conditions, enthusiasm for innovative technologies like artificial intelligence, and insights gained from partnerships with clinical care centers. This enables them to create novel solutions that address the unmet needs in the clinical care of chronic neurological conditions, primarily neurodegenerative diseases, epilepsy, and MS.

Combinostic's Core Products and Solutions

At the heart of Combinostics' innovations is their brain segmentation algorithm. This sophisticated tool empowers clinicians by providing critical insights into differentiating among some of the most complex neurodegenerative conditions.



Image Courtesy Combinostics

MRI brain imaging is a critical tool for assessing neurological disorders such as multiple sclerosis (MS), traumatic brain injury (TBI), epilepsy, and dementia. cMRI provides fully automated, objective quantification and segmentation of patterns in brain volume and lesions from MRI images, including subtle changes and characteristics that are difficult to detect using visual assessments alone.

Combinostic's Key Benefits and Features

cMRI ensures consistently high-quality reads and increases throughput by reducing the time spent per image read. Its automated reporting features easy-to-read, objective, clinically meaningful data to improve collaboration and communication with referring clinicians and help reduce image-related queries.

- Increase Productivity by highlighting key findings from images and saving time assessing neurological studies.
- Improve consistency and reproducibility by objective quantification of disease-specific abnormalities and patterns to identify subtle changes and patterns in brain volume and lesions.
- Increase interpretability by disease-specific imaging biomarkers, especially for dementia and MS.
- Improve communication by easy-to-understand disease-specific reports (dementia, MS, TBI and epilepsy), tailored for both clinicians and/or patients and available in light or dark theme.

TERARECON

IMAGING BIOMETRICS

ImagingBiometrics
CREATING THE STANDARD

Imaging Biometrics' Mission

Imaging Biometrics initiated its mission with the launch of the first commercial DSC-MRI perfusion analysis platform on May 15, 2008. Rooted in a commitment to advance neurological imaging, our journey seeks to offer pioneering solutions in DSC-MRI analysis through innovative and diligently validated approaches.



T1 and T1+C (pre- and post-contrast) images commonly collected for brain exams. top row: Pre- and post-contrast images commonly collected for brain exams. bottom row: IB Delta T1 and IB Neuro sRCBV maps

Imaging Biometrics' Background and Expertise

With a foundation solidly built upon the vast expertise of co-founder Dr. Kathleen Schmainda, IB Neuro brings to the fore an unparalleled depth in neurological research and understanding. The platform integrates the most-proven contrast leakage algorithm, an embodiment of over two decades of rigorous studies and steadfast validation, offering a unique and scientifically substantiated approach to DSC-MRI analysis.

Imaging Biometrics' Core Products and Solutions

The IB Neuro platform stands distinguished as the solitary entity in the realm of DSC-MRI analysis that employs patented standardization technology, thus ensuring that the provision of standardized rCBV is not just consistent but also repeatable, backed by numerous methodologically sound studies.

IB Neuro's Key Benefits and Features

IB Neuro, the only DSC-MRI analysis software used in national multi-center clinical trials incorporating DSC-MRI, has showcased its unique ability to reliably analyze data across all MRI vendor platforms. The insights derived from IB Neuro-generated rCBV have proven critical in predicting outcomes, establishing it as a trusted name in various study contexts.

IB Neuro's Clinical Applications and Impact

The ability of IB Neuro-generated rCBV to be independently validated with tissue samples highlights its capability in accurately estimating tumor burdens and discerning tumors from treatment effects. This precision in analytical applications has proven imperative in complex clinical scenarios such as glioblastoma tumor progression, enabling a nuanced reevaluation of imaging definitions and fortifying its role in survival prediction.

The integration of IB Delta T1 Maps into this framework has further refined the clinical impact, offering additional quantitative metrics for tissue characterization that bolster the platform's diagnostic and prognostic capabilities.

Through comparison studies, IB Neuro has validated its effectiveness by not only demonstrating notable accuracy against other platforms but also by reliably using 50% less gadolinium contrast agent, reflecting a commitment to both efficacy and ethical practices in neurological imaging.



Typical output generated by IB Software: IB Neuro and IB Delta T1 maps

TERARECON

Cercare Medical

CERCARE MEDICAL

Cercare Medical's Mission

Dedicated to enhancing clinical decision-making through advanced neuroimaging solutions, Cercare Medical pioneers in offering invaluable, detailed insights into cerebral blood flow and volume, with a commitment to supporting healthcare professionals in delivering optimized patient management.

Cercare Medical's Background and Expertise

Rooted in over 25 years of scrupulous research from the Center of Functionally Integrative Neuroscience at Aarhus University Hospital, Denmark, Cercare's offerings are solidly backed by more than 70 publications, affirming a foundation built upon comprehensive and dedicated scientific exploration in the realm of AI* and Perfusion Imaging.

Cercare Medical's Core Products and Solutions

Emphasizing a deep dive into neurovascular function assessments, Cercare Perfusion stands out as a fully automated and vendor-neutral solution. It intricately combines perfusion technology with patented biomarkers and artificial intelligence,* ensuring precise volumetric measures that directly influence clinical strategies,[16] especially in contexts such as vascular pathology, tumors, dementia, and stroke.

Cercare Medical's Key Benefits and Features

- Streamlined Operations: Offering a 0-click integration and automated features like motion correction and smart AIF, Cercare Perfusion enhances workflow effectively.
- Standardized Analysis: A commitment to perfusion analysis standardization
- In-depth Insights: High-quality maps and unique perfusion biomarkers like CBV, CBF, MTT, CTH, OEF, and rCMRO2 grant profound insights into brain tissue viability.
- Lesion Identification & Quantification: Comprehensive analysis and quantification capabilities.
- Flexible Approach: The flexibility of utilizing either a threshold method or an AI method,* which incorporates several maps and biomarkers, especially vital for stroke management.

Cercare Medical's Clinical Applications and Impact

Facilitating more than just imaging, Cercare presents clinicians with enriched data and maps, illustrating not only blood flow and volume but also paramount factors like oxygen availability, thereby playing a critical role in assessing and managing a diverse array of conditions, including oncology, Alzheimer's disease, and neoplasia.

With recognition echoed through more than 70 publications and a history interwoven with 25 years of dedicated research, Cercare Medical has shaped its solutions by adhering to scientifically validated practices and generating patented biomarkers that underpin the capabilities of their offerings.

* Not available in US

16 The Role of the Cerebral Capillaries in Acute Ischemic Stroke: The Extended Penumbra Model. Sage Journals. https://journals.sagepub.com/doi/10.1038/jcbfm.2013.18

TERARECON

HOW AI-POWERED SOLUTIONS CAN HELP ENHANCE NEUROLOGICAL DISEASE DIAGNOSIS

AI-powered solutions have revolutionized neurological disease diagnosis by analyzing vast amounts of data with unprecedented speed and accuracy. The integration of AI into our clinical practice offers several benefits.

Key Benefits

Early Detection

AI algorithms can detect subtle changes in brain imaging or clinical data, allowing for early detection of neurological diseases.[17] This enables clinicians to initiate interventions at earlier stages when treatments are most effective.

Precision and Objectivity

AI-powered solutions provide objective and quantitative assessments of medical imaging, reducing the risk of subjective interpretations. This precision may enhance diagnostic accuracy or reduce diagnostic errors potentially improving patient outcomes.

Multimodal Data Fusion

AI algorithms can integrate data from various sources, such as imaging, genetics, and clinical history. By combining multiple data types, AI provides a comprehensive view of each patient's condition, aiding in more accurate diagnoses and personalized treatment plans.

Streamlining Treatment Decisions with AI Algorithms

In addition to aiding clinicians in diagnosis, AI algorithms streamline treatment decisions by:

Treatment Prediction

AI-driven predictive models analyze patient data and treatment outcomes to help us predict which treatments are likely to be most effective for individual patients. This personalized approach can improve treatment response rates and reduce adverse effects.

Drug Repurposing

AI algorithms can identify potential therapeutic options by repurposing existing drugs for new applications. This approach accelerates the development of novel treatments for neurological diseases and reduces the time and cost associated with drug discovery. Specifically, by providing more accurate imaging biomarkers, fewer study subjects are needed to statistically power a study.

17 https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiduoSFi6iBAxUUk2oFHS2vCLcQFnoECA8QAQ&url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9227741%2F&usg=AOvVaw1MIpjSemb1BN4lTTarxrgH&opi=89978449

Case Studies Demonstrating the Efficacy of AI in Neurological Care

Case Study 1: Early Diagnosis of Alzheimer's Disease

Using Combinostics' AI algorithms, a patient with mild cognitive impairment was accurately diagnosed with early-stage Alzheimer's disease. Early intervention with disease-modifying therapies significantly slowed disease progression, preserving cognitive function for an extended period.

Case Study 2: Personalized Treatment for Epilepsy

AI-powered analysis of neuroimaging data revealed specific brain regions responsible for recurrent seizures in a patient with drug-resistant epilepsy. This guided surgical planning resulted in successful seizure control and improved quality of life.

Case Study 3: Precision Treatment for Multiple Sclerosis

Cercare's clinical decision support system analyzed a patient's neuroimaging, genetic, and clinical data to recommend a targeted disease-modifying therapy. The patient's disease activity was effectively suppressed, leading to reduced relapses and disability progression.

Synergy of Combinostics, Imaging Biometrics, and Cercare Medical

Embracing AI-powered solutions from Combinostics, Imaging Biometrics, and Cercare, we can enhance physicians neurology practice, enabling them to improve disease detection and identification, while helping identify personalized treatments that maximize patient outcomes. The integration of these AI technologies, alongside TeraRecon's Neurology Suite on the Eureka Clinical AI Platform, further strengthens our ability to deliver patient-centered, data-driven care, streamlining IT consolidation and workflow across the patient care pathway. Let us embark on this journey of innovation, harnessing the power of AI to revolutionize neurological disease identification and treatment.

The Value of Interoperability in Neurological Clinics

In modern healthcare, seamless data exchange and interoperability are crucial for delivering efficient and effective patient care. The collaboration of Combinostics, Imaging Biometrics, and Cercare brings a new level of synergy to neurological clinics, enhancing the value of interoperability in several ways:

- **Unified Data Access:**
  By integrating Combinostics, Imaging Biometrics, and Cercare solutions, clinicians gain access to a comprehensive patient dataset, including neuroimaging, genetic profiles, and clinical history. This unified data approach help streamline decision-making, which can lead to more accurate diagnoses and personalized treatment plans.
- **Cross-Platform Compatibility:**
  Interoperability ensures that data from each platform can be seamlessly exchanged and utilized within a single environment. Clinicians can now access and interpret data from multiple sources without the need for manual data transfer, saving valuable time and improving efficiency.
- **Real-Time Collaboration:**
  The interconnectedness of these solutions allows for real-time collaboration among different specialties within the neurological clinic. This multidisciplinary approach fosters more informed discussions and decisions, leading to improved patient outcomes and better quality of care.

How Combined Solutions Enhance Diagnosis Accuracy and Treatment Planning

The collaboration of Combinostics, Imaging Biometrics, and Cercare provide AI-driven insights which may significantly enhance the physicians ability to provide an accurate diagnosis and treatment plan.

Enhanced Data Analysis

Maximizing the Potential of AI in Neurological Clinics

The synergy of Combinostics, Imaging Biometrics, and Cercare offers a transformative impact on neurological clinics, maximizing the potential of AI in the following ways:

Advancing Precision Medicine:

AI-driven insights facilitate precision medicine by tailoring treatments to each patient's unique profile. Clinicians can now offer personalized therapies that address the specific needs and characteristics of individual patients, leading to improved clinical outcomes.

Accelerating Research and Innovation:

The integrated AI solutions enable clinicians to contribute valuable data to research initiatives and clinical trials. This collaborative approach fosters a culture of innovation, accelerating advancements in neurological care and expanding our understanding of neurological diseases.

Advantages of TeraRecon's Neurology Suite on the Eureka Clinical AI Platform

Introduction to TeraRecon's AI-Powered Suite

The strength of the Neurology Suite provides customers the flexibility to choose the algorithms that fit the specific needs of the Neurology workflows within their hospitals.

TeraRecon's Neurology Suite on the Eureka Clinical AI Platform is a comprehensive AI-powered solution designed to optimize the neurology practice. This suite combines the strengths of Combinostics, Imaging Biometrics, and Cercare within a unified platform, streamlining clinical workflows, and enabling seamless data exchange.

IT Consolidation and Workflow Optimization

TeraRecon's Neurology Suite offers IT consolidation, simplifying data management by integrating multiple AI-powered solutions. The centralized platform ensures easy access to patient data, enabling clinicians to focus on diagnosis and treatment without the burden of managing multiple applications.

Enhancing Patient Care Pathway through Seamless Integration

The Neurology Suite's seamless integration with existing clinical systems promotes a smooth patient care pathway. Data flow between Combinostics, Imaging Biometrics, and Cercare is seamless, eliminating silos and enhancing collaboration among clinicians, radiologists, and other specialists.

Benefits of Leveraging TeraRecon's Neurology Suite for Neurological Clinicians

Neurology Suite is a comprehensive, vendor-neutral suite of hand-selected Neurology AI algorithms that aid in the analysis and interpretation of neuroimaging treatment decisions for neurovascular diseases, neurodegenerative diseases, brain lesions (both cancerous and noncancerous), and epilepsy.

- A comprehensive collection of AI algorithms for various chronic neurological disorders
- One centralized location for managing, processing, and locating neurological images
- Arm your team with reliable clinical insight capabilities
- Easy management of longitudinal analysis of serial scans
- Curated, elite performing algorithm suite provides a large range of data to potentially aid physicians with neurological diseases
- Recognized AI vendors for confidence in diagnosis and treatment

CONCLUSION

Neurological diseases present significant challenges in clinical practice, necessitating advanced solutions to enhance diagnosis and treatment.

AI-powered solutions from Combinostics, Imaging Biometrics, and Cercare play a critical role in improving neurological care, offering precise data to aid physicians in diagnoses and providing personalized treatment options.

Leveraging TeraRecon's Neurology Suite on the Eureka Clinical AI Platform empowers clinicians to enhance patient outcomes by streamlining workflows, enabling seamless data exchange, and providing access to advanced AI-driven insights. Together, this collaboration sets a new standard for neurological care, paving the way for improved patient outcomes and clinical excellence.